Gilead Sciences, Inc. · Healthcare
$127.23
-17.9%
Jun 17, 2026
D
WeakGraded against GILD's own history at this drawdown — not the market's.
What it means: GILD's own history does not strongly favor buying at this level yet.
What to do: Consider watching and waiting for a deeper dip or a higher grade.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for
Three plain-English paragraphs — current state, historical base rate, and interpretation — so you walk away with context, not a dashboard.
In plain terms: GILD is 17.9% below its highest-ever price. Dipsern checks every past time it was this far down and grades how the next 90 days usually went.
Right now GILD — Gilead Sciences — is in a moderate correction, down 17.9% from its record high. Last price: $127.23. Corrections in this band are common during macro repricings (rate scares, sector rotations, earnings shocks). The question is whether the cause is durable or transient.
History at this drawdown level is well-populated for GILD — 839 confirmed observations in the 20%-to-15% band. The Dipsern engine uses these to compute a rolling median rather than a mean, because medians are robust to the kind of fat tails you find in us stocks return distributions. The win rate (% of episodes that closed positive after 90 days) is shown in the segments table below.
For US large-caps, drawdowns of 20-30% are typically driven by macro repricing (rates, earnings, sector rotation). Single-name 50%+ drawdowns are usually structural — the signal alone won't tell you which, but the segments table will show whether prior episodes recovered. This is the band where most successful "buy the dip" strategies have historically operated. The median forward return here for GILD is in the full app, alongside the segment-level win rate.
Five tickers closest to GILD's distance from all-time high. Same category, one tap away.
Dipsern segments the full drawdown range into 20 equal-width bands. The table shows the number of confirmed historical observations in each band for GILD. Median forward returns, win rates, and prediction errors are available in the full analysis.
We segment 40+ years of GILD's price history into 20 equal-width drawdown bands and compute forward median returns, win rates, and prediction error per band. No look-ahead bias. Pure NumPy. Open math, gated numbers.
Years of history
40+
Drawdown bands
20
Look-ahead bias
None
Data sources
4
See the Dipsern grade, median returns, win rates, prediction accuracy, 8 interactive charts, historical price paths, and a plain-English verdict for GILD.
Dipsern is research and a second opinion — not a broker. You'd buy GILD at your own broker.
Analyze GILD FreeNo credit card required · 5 free analyses per month
Signal computed Jun 17, 2026 using default parameters (90-day return period, 20 segments, 0.95 decay). Data sourced from Yahoo Finance, Binance, CoinGecko, and Steam Market.